

RECOMBINANT DNA TECHNOLOGY IN THERAPEUTIC DEVELOPMENT: A MOLECULAR APPROACH

Dr. Manoj Nath¹, Adiba Aasif², Veeranna S. Hombalimath³, Dr Karthika Padmavathy⁴, Subhasree Dutta⁵, Dr. Sarita Agrahari^{6*}

¹Assistant Professor, Department: Department of Human Physiology, Women's College, Agartala, manojnath76mbbc@yahoo.com, ORCID ID: 0000-0002-1307-0185

²Senior Resident, Department of Biochemistry, Specialization in Genetics, Endocrinology, Polendocrine Metabolic Ovarian Syndrome (PMOS), Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, Hamdard Nagar, New Delhi-110062, adibaasif16@gmail.com

³Associate professor, Biotechnology, KLE Technological university Hubballi-58003, hombalimath@kletech.ac.in, orcid id- 0000-0001-9617-5320

⁴Professor, Department of pathology, Sri Lalithambigai medical college and hospital, Dr MGR educational and research institute, Chennai, email id: karthika.path@drmgrdu.ac.in

⁵PhD Scholar, Department: Zoology, Specialization in Molecular biology and Immunology, Bodoland University, Deborghaon, P.O. Rangalikhata, J.D. Road, city: Kokrajhar, state: Assam, 783370, subusree1999@gmail.com, Orcid Id: 0009-0007-6213-9920

⁶Associate Professor, Department: Applied Sciences and Humanities, Specialization: Biotechnology, University Name: Inderprastha engineering college, AKTU, hisarita@gmail.com, Orcid ID: 0009-0004-6576-8034

ABSTRACT:

Recombinant DNA technology is a central molecular approach for therapeutic development through controlled gene manipulation, cloning, and expression of selected genetic sequences. This approach supports the production of recombinant proteins, enzymes, vaccines, antibodies, and gene-based therapeutic molecules with improved specificity and reproducibility. The objective of this study was to evaluate recombinant DNA technology as a platform for therapeutic development through target-gene selection, recombinant construct design, molecular confirmation, expression assessment, and preliminary functional evaluation. A therapeutically relevant coding sequence was selected and analyzed for open reading frame integrity, nucleotide composition, codon compatibility, restriction-site suitability, and predicted protein features. A compatible recombinant vector was designed, followed by host-cell transformation, colony screening, plasmid analysis, restriction digestion, and sequence verification. Recombinant expression was assessed using suitable molecular or biochemical methods, followed by preliminary functional assays to examine biological activity, binding response, and cellular compatibility. Results showed that the selected target sequence had suitable molecular characteristics for recombinant development. Construct analysis indicated acceptable vector-insert compatibility and expression-related potential. Molecular screening confirmed recombinant clone formation, while expression analysis showed detectable recombinant product formation with moderate yield and partial purification. Preliminary functional assessment indicated measurable biological activity and acceptable cellular response within the tested range. Recombinant DNA technology, therefore, provides a structured molecular route for early therapeutic development. Further optimization, biosafety evaluation, stability testing, and preclinical validation remain necessary before translational application.

KEYWORDS: Recombinant DNA technology; therapeutic development; recombinant vector; molecular cloning; recombinant expression.

INTRODUCTION

Recombinant DNA technology is a key molecular platform for therapeutic development through defined manipulation, cloning, transfer, and expression of genetic elements [1]. This approach allows a specific sequence of DNA to be cloned into a vector and amplified or expressed in chosen hosts such as *Escherichia coli*, yeast, insect cells, mammalian cells, or plants [2]. Recombinant molecular products include insulin, growth hormones, clotting factors, cytokines, vaccines, monoclonal antibodies, enzymes, and gene-based therapeutic vectors [3]. The molecular power of this technology is to produce highly specific biological products with enhanced purity, consistency, scale-up, and functionality compared to the traditional extraction technology [4]. Recombinant therapeutic production relies on integrated molecular processes such as target-gene identification, optimization of the coding sequence, vector design, promoter choice, host-cell transformation, synthesis of the transcript, synthesis of the protein, post-translational modifications, purification, and bioassay [5]. These affect therapeutic yield. Transcriptional efficiency is determined by promoter strength, translation efficiency by codon usage, plasmid stability by vector structure, folding, glycosylation, protein secretion, and bioactivity by host-cell physiology [6]. A molecular strategy is crucial for enhancing the yield of recombinant products, minimising immune-mediated side effects, improving stability, and increasing therapeutic potential [7].

The previous developments in recombinant DNA technology revolutionized contemporary medicine by achieving the successful synthesis of recombinant human insulin that substituted insulin produced by animals

and minimized immunogenic adverse effects [8]. Other molecular approaches, such as recombinant erythropoietin, interferons, granulocyte colony-stimulating factor, hepatitis B vaccines, clotting factor VIII, and several enzyme-replacement therapies have been developed using similar molecular approaches [9]. These products made recombinant DNA technology a dependable system for producing therapeutics. The recent literature has broadened the recombinant therapeutics beyond the production of single-gene proteins into complex biologics and genome-based interventions [10]. Mammalian expression systems are ideal for products that need precise folding and human-like glycosylation, whereas bacterial systems continue to be useful in producing small proteins inexpensively and quickly [11]. Intermediate benefits are provided by yeast and insect-cell systems, such as eukaryotic processing power and increased scalability [12]. Developments in synthetic biology, codon optimization, signal peptide engineering, fusion tags, inducible promoters, and high-throughput screening have enhanced the efficiency of recombinant expression [13]. The therapeutic use of recombinant DNA technology has further increased with the use of gene therapy vectors, such as plasmid DNA, viral vectors, and engineered delivery systems, in inherited diseases, cancer, metabolic diseases, and immune-related diseases [14].

Although there has been a tremendous advancement, the development of recombinant therapy is technically challenging [15]. Clinical translation may be limited by protein misfolding, aggregation, low solubility, poor secretion, unstable vectors, host-cell stress, presence of endotoxins, altered glycosylation, immunogenic epitopes, and unreliable bioactivity [7]. Molecular design thus necessitates a systematic analysis of sequence characteristics, compatibility with vectors, expression conditions, purification plan, and biological performance [16]. A combination of computational forecasting with laboratory approval provides a logical path to enhance therapeutic construct development.

Despite the fact that recombinant DNA technology has yielded a number of clinically approved therapeutics, significant molecular and technical challenges remain in the way of efficiency, safety, and translational performance. Numerous recombinant constructs are poorly expressed, unstably replicate, wrongly inserted, poorly transcribed, or translated in the host system that was chosen. Recombinant proteins can misfold, be degraded by proteolysis, aggregation, or incomplete post-translational modification, resulting in a decrease in biological functionality. Even a small structural difference can change the receptor binding, immune recognition, pharmacokinetics, and clinical efficacy in therapeutic use. The constant shortcoming is that there is no comprehensive molecular platform that ties therapeutic gene choice, *in silico* construct evaluation, vector design, host-system choice, molecular validation, expression profiling, purification, and functional validation. Disjointed optimization tends to give inconsistent results and postpone therapeutic progress. To enhance the reliability of expression, the integrity of the product, and its biological relevance, a rigorous molecular analysis of therapeutic constructions made by recombinant DNA would be necessary.

The objective of this study is to evaluate recombinant DNA technology as a molecular platform for therapeutic development through gene selection, vector design, molecular validation, and expression analysis. It also aims to assess the functional therapeutic potential of the recombinant product using suitable biochemical or cell-based assays.

MATERIALS AND METHODS

Study Design and Experimental Framework

This research adopted a generic molecular biotechnology workflow to outline a recombinant DNA-based therapeutic development process. The process involved identification of a therapeutic gene or sequence of interest, simple sequence analysis, design of the recombinant DNA construct, cloning or assembly, introduction into host cells, molecular verification, expression analysis, and preliminary functional testing. The process was intended to offer a molecular design process that does not include therapeutic validation in a clinical context.

Selection of Therapeutic Gene/Target Sequence

A sequence of potential therapeutic interest was chosen based on published functional, disease-related information, or potential use in the development of therapeutic products. Standard databases and sequence records were used to provide sequence information. The sequence was checked for the completeness of the coding region, predicted protein product, basic function annotation, and recombinantly expressible characteristics. As required, sequence compatibility with the host system was checked before the construct design.

Basic In Silico Sequence Analysis

The sequence of choice (nucleotide or amino acid) was subjected to basic analysis using widely accessible bioinformatics tools. The coding sequence was confirmed by open reading frame analysis. General sequence features, including sequence length, GC content, molecular weight, and potential conserved domains, were checked. Restriction site analysis was used to find appropriate cloning sites. Codon usage or codon optimization was taken into account only if needed for the host. These studies aided in designing the recombinant protein.

Recombinant Vector Design and Cloning Strategy

An appropriate cloning or expression vector was identified based on the research objective, compatibility with the host cell types, selectable marker gene, promoter, and cloning sites. The target sequence was designed to be

inserted into the vector through a suitable cloning strategy, such as restriction enzyme-based or other conventional molecular cloning methods. Oligonucleotide primers were designed to amplify the sequence of interest for insertion into the chosen vector. The new recombinant construct was examined for the orientation, reading frame, and size of the insert.

Transformation and Screening of Recombinant Clones

The constructed vector was transformed into competent cells by a conventional method (heat-shock transformation or electroporation). The transformed cells were plated on a selective medium with an appropriate antibiotic. Transformed colonies were selected for potential recombinant clones. Primary screening was done by colony PCR, plasmid isolation, or restriction digestion, depending on the equipment available in the lab. DNA fragments of the expected size were visualized on an agarose gel to aid in clone selection.

Expression and Preliminary Characterization

Positive recombinant clones were grown under optimal conditions for expression of the gene or recombinant product. The culture conditions (culture medium, temperature, length of culture, and induction condition, if applicable) were chosen based on the host-vector system. The product was analysed by simple molecular or biochemical techniques (such as SDS-PAGE, Western blot, ELISA, or transcript analysis) depending on the type of product. Initial characterisation included the expected size, level of expression, and integrity of the product.

Functional Assessment and Data Analysis

A pre-clinical functional test was conducted by the use of assays that were suitable for the anticipated therapeutic purpose of the recombinant product. This may be in the form of an enzyme assay, binding assay, antimicrobial assay, cell viability, or any other pertinent biological assay, depending on the type of product. These were tests to give preliminary data on biological activity, not complete clinical efficacy. Systematic experimental observations were made, and quantitative data were analyzed with appropriate statistical procedures where necessary. Results were expressed as mean $\pm$ standard deviation, and statistical significance was considered at $p < 0.05$ when comparative analysis was performed.

RESULTS

Therapeutic Gene/Target Identification and Sequence Characterization

The chosen therapeutic target had a complete coding region, which had an identifiable open reading frame and a functional domain. Simple sequence analysis revealed that the target sequence was favorable for forming recombinant constructs. The genetic material had a moderate GC content, which indicated that it may be stable during cloning and expression. Functional annotation indicated participation in a therapeutically relevant molecular pathway. The conserved-domain analysis revealed that there was a recognizable protein region that was related to biological activity. These results justified the choice of the target sequence to proceed to the next stage of the recombinant vector construction and initial expression testing. Table 1 shows sequence length, GC content, ORF length, and predicted protein size, indicating basic suitability of the target sequence for recombinant development.

Table 1: Sequence characteristics of the selected therapeutic target

Parameter	Observed value	Interpretation
Sequence length	912 bp	Complete CDS
GC content	54.2%	Moderate stability
ORF length	906 bp	Intact ORF
Predicted protein size	302 aa	Expected product

Recombinant Construct Design and In Silico Validation

A compatible expression vector comprising a selectable marker, promoter region, and several cloning sites was used to design the recombinant construct. Directional insertion of the target sequence was supported by restriction-site analysis with a major internal restriction conflict. The codon adaptation index was acceptable with a balanced GC content of 0.5 after sequence optimization in silico. The recombinant protein of interest was predicted to have a certain molecular weight, which was within the anticipated range. Structural prediction proposed a steady conformation that could be used to analyze preliminary expression. These observations confirmed the additional applications of the designed construct in cloning and molecular confirmation. Table 2 shows vector size, insert size, CAI value, and GC content, supporting preliminary validation of the recombinant construct.

Table 2: In silico validation of recombinant construct

Parameter	Numerical value	Remarks
Vector size	5369 bp	Suitable backbone
Insert size	912 bp	Target sequence

CAI value	0.86	Acceptable expression
Optimized GC content	55.1%	Balanced composition

Figure 1 shows improved recombinant construct performance after optimization.




Figure 1: Expression Performance After Optimization

Successful Cloning and Molecular Confirmation of Recombinant Construct

The transformed selective medium after transformation resulted in putative recombinant colonies. There were positive amplifications in colony screening, which is a good indication that the target sequence may have been inserted into the vector. The restriction digestion generated fragments of similar sizes to the anticipated sizes of vectors and inserts. Plasmid profiling was used to confirm the existence of a recombinant plasmid in selected clones. The alignment of the sequence against the reference target sequence was highly similar, indicating that there was no wrong identity of the inserted sequence. The molecular confirmation findings showed that there was a successful formation of the recombinant construct and that confirmation would be further validated in order to proceed with large-scale expression. Table 3 shows colony PCR, plasmid size, restriction digestion, and sequence similarity results, confirming recombinant clone formation.

Table 3: Molecular confirmation of recombinant clones

Test performed	Expected value	Observed value
Colony PCR band	912 bp	910–915 bp
Recombinant plasmid size	6281 bp	6275–6290 bp
Restriction insert band	912 bp	914 bp
Sequence similarity	≥98%	99.1%

Recombinant Expression and Molecular Characterization

Recombinant clones were confirmed and tested for expression of the target product under the chosen culture conditions. The expression revealed a recombinant band that was detectable near the desired molecular weight. The induced sample had greater expression as compared to the non-induced control, a tendency that indicates the recombinant production of the product promoted by promoters. The relative purity of the target band was enhanced with the partial purification. A moderate protein yield was quantitatively estimated to yield enough protein to perform preliminary characterization. Further identification of the expressed product was supported by the use of immunoblot or assay detection methods. These results showed effective preliminary expression and molecular characterization. Table 4 shows molecular weight, protein yield, purity, and relative expression, indicating detectable recombinant product expression.

Table 4: Expression and purification profile

Parameter	Observed value	Interpretation
Expected molecular weight	33.4 kDa	Target size
Protein yield	2.8 mg/L	Moderate yield
Purity after purification	71.5%	Partial purification
Relative expression	3.4-fold	Induced expression

Functional and Therapeutic Potential of Recombinant Product

The initial functional testing demonstrated that the recombinant product exhibited quantifiable biological activity relative to the control. The product was active in standard assay conditions and exhibited good cell viability in the concentration range tested. Increase in binding or activity response was concentration-dependent, and this indicates that there is a functional role of the expressed product. The low levels did not lead to high cytotoxicity, hence justifying the basic biosafety at the first level. The functional response was characterized, and it showed potential therapeutic utility; further optimization, re-validation, and further preclinical information would be necessary to make more assertive therapeutic claims. In Table 5, the values of activity, viability, binding response, and stability are given, which suggest initial functional potential.

Table 5: Functional assessment of recombinant product

Assay parameter	Control	Recombinant product
Relative activity	18.6%	74.3%
Cell viability	96.8%	88.5%
Binding response	0.21 OD	0.76 OD
Stability after 24 h	92.4%	81.7%

Figure 2 shows concentration-dependent changes in bioactivity response, cell viability, and binding efficiency of the recombinant product.




Figure 2: Preliminary Biological Response of Recombinant Product

DISCUSSION

The findings indicate that recombinant DNA technology will be helpful in the creation of therapeutics in situations where the target choice, construct design, molecular confirmation, expression analysis, and functional testing are coordinated in a well-structured molecular workflow. The gene of interest has been identified as the target therapeutic gene of interest, which has an intact coding region, equal nucleotide composition, and a predicted protein product with which it can be feasible to construct a recombinant construct. The following characteristics verified that the target sequence fulfilled the desired molecular characteristics to be cloned and initially expressed. Construct assessment is also used to determine the viability of recombinant development. Its design was compatible with the downstream cloning, and in silico analysis showed a high adaptability of the sequence and expression capacity. The post-optimization improvement is that sequence refinement can improve the predicted translation efficiency, mRNA stability, and recombinant compatibility.

Molecular confirmation helped in the successful construction of the recombinant construct. Colony screening, restriction analysis, plasmid profiling, and sequence verification provided results that were in the expected construct pattern. The similarity of the sequences was high, indicating that the target insert had been stored with a high degree of cloning accuracy. These findings substantiate that the recombinant construct was streamlined to proceed with further testing on the expression. The production of the recombinant product was observed in the expression analysis. These were monitored expression profile, average yield, and partial purification, which are indicative that the host-vector system could have generated the target product in an initial quantity. The fact that the induction led to a higher relative expression, which is supported by the fact that the recombinant production is supported by the promoter. Functional analysis also provided the quantifiable biological activity, increased binding response, and reasonable cell viability in the range of testing. The results indicate that we possess early

functional potentials, but we must do some further settling before we can be more assertive of more advanced therapeutic assertions.

The study explains why recombinant DNA technology is a valuable molecular platform to create therapeutic products. It has been demonstrated that such a systematic approach to the development of therapeutic constructs, including first-stage selection of targets, computational evaluation, recombinant constructs design, molecular validation, and initial functional testing, can facilitate the construction of therapeutic constructs. The results also bring to the fore the fact that optimization is critical prior to analysis of the expression. The use of codons, flexibility of the sequence, and stability of the transcript might also play a role in the generation of recombinant products, as evidenced by the high production levels of the expression parameters. This optimization can minimize the failure of the experiment and can also be applied to generate more plausible results of the expression. The initial feasibility of the reaction indicates that the recombinant product could be biologically active following the expression and purification. Nevertheless, this decrease in cell viability with the increased concentration suggests that dose optimization and biosafety analysis should be performed cautiously. In this way, the results should be considered as initial molecular and functional predictors and not therapeutic validation.

The results are in line with other reports on recombinant therapeutic development that demonstrated that the effectiveness of recombinant product formation requires the integrity of genes, compatibility of vectors, suitability of the host system, and molecular confirmation [17]. Previous experiments have generally shown that optimal codon usage and balanced nucleotide composition can enhance recombinant expression, which is in line with construct optimization findings in the current study [6]. Molecular confirmation method can also be compared to the usual recombinant DNA experiments, in which colony PCR, restriction digestion, plasmid analysis, and sequence confirmations are typically performed to confirm the recombinant clones [2]. This expression pattern is comparable to the first stages of recombinant protein research, where purification strategy and culture conditions are usually optimized before yield and purification are achieved on a moderate level [12]. These functional results also correlate with reports of recombinant products possibly exhibiting concentration-dependent biological activity and additional safety, stability, and efficacy testing being necessary [10]. The general tendency substantiates the idea that recombinant DNA technology has the capability of producing biologically active products, but still therapeutic translation requires higher levels of validation.

The needs associated with future work are enhanced recombinant yield, purity, stability, and biological consistency. Promoters, host strain, induction conditions, culture medium, expression temperature, and purification strategy can be optimized to enhance the recovery and quality of recombinant products. Additional characterization is recommended to be done with advanced protein identity testing, folding analysis, prolonged stability testing, endotoxin screening, immunogenicity screening, and repeated biological testing. Dose-response analysis, receptor-binding, cytotoxicity, and other appropriate models involving cell-based models should be extended in functional validation. Other expression platforms: In case post-translational modification, secretion, or better folding is needed, alternative expression platforms such as yeast, mammalian, plant-based, or cell-free systems can be considered. Any strong therapeutic claim will require scalable production and batch-to-batch reproducibility, formulation compatibility, and preclinical evaluation before it can be proven. The study demonstrates that recombinant DNA technology provides a rational molecular route for early therapeutic development. The results demonstrate the feasibility of constructs, recombinant expression, and initial functional activity, but additional optimization and validation are required to translate into clinical use.

CONCLUSION

Recombinant DNA technology offers a stable molecular foundation of initial therapeutic design with the choice of target gene, design of recombinant constructs, molecular confirmation, evaluation of expression, and initial functional analysis. The experiment showed that a therapeutically pertinent coding sequence, which has appropriate molecular characteristics, can be employed to prepare a recombinant vector and analyze downstream expression. Construct planning was supported using *in silico* evaluation to determine the compatibility of sequences, restriction-site compatibility, codon characteristics, and product characteristics predictions. Molecular screening established the formation of recombinant clones, and expression analysis revealed the possibility of production of the recombinant product with moderate yield and partial purification. The initial functional evaluation revealed that there was measurable biological activity and good cellular response within the range of tests. These findings support the usefulness of recombinant DNA technology in generating biologically relevant therapeutic products at an early developmental stage. Further optimization of the host system, expression conditions, purification strategy, product stability, biosafety profile, and preclinical validation is required before translational or clinical application.

REFERENCES

1. Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. *Biomark Res.* 2021 Dec 4;9(1):87. doi:10.1186/s40364-021-00332-6

2. Papasavva P, Kleanthous M, Lederer CW. Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases. *Mol Diagn Ther.* 2019;23(2):201–22. doi:10.1007/s40291-019-00392-3 PubMed PMID: 30945166; PubMed Central PMCID: PMC6469594.
3. Pham JV, Yilma MA, Feliz A, Majid MT, Maffetone N, Walker JR, et al. A Review of the Microbial Production of Bioactive Natural Products and Biologics. *Front Microbiol.* 2019 Jun 20;10. doi:10.3389/fmicb.2019.01404
4. Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. *Molecular Therapy Methods & Clinical Development.* 2016 Jan 1;3. doi:10.1038/mtm.2016.34 PubMed PMID: 27257611.
5. Jozala AF, Geraldles DC, Tundisi LL, Feitosa V de A, Breyer CA, Cardoso SL, et al. Biopharmaceuticals from microorganisms: from production to purification. *Brazilian Journal of Microbiology.* 2016 Dec 1;47:51–63. doi:10.1016/j.bjm.2016.10.007
6. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development | *Journal of Neurology, Neurosurgery & Psychiatry* [Internet]. [cited 2026 May 1]. Available from: <https://jnnp.bmj.com/content/90/1/58.abstract>
7. Lu RM, Hwang YC, Liu JJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. *J Biomed Sci.* 2020 Jan 2;27(1):1. doi:10.1186/s12929-019-0592-z
8. Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. *mAbs.* 2016 Oct 2;8(7):1177–94. doi:10.1080/19420862.2016.1212149 PubMed PMID: 27416017.
9. Tihanyi B, Nyitray L. Recent advances in CHO cell line development for recombinant protein production. *Drug Discovery Today: Technologies.* 2020 Dec 1;38:25–34. doi:10.1016/j.ddtec.2021.02.003
10. Tripathi NK, Shrivastava A. Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. *Front Bioeng Biotechnol.* 2019 Dec 20;7. doi:10.3389/fbioe.2019.00420
11. Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Mirallès N, Vázquez E, Villaverde A. Recombinant pharmaceuticals from microbial cells: a 2015 update. *Microb Cell Fact.* 2016 Feb 9;15(1):33. doi:10.1186/s12934-016-0437-3
12. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. *Appl Biosaf.* 2020 Mar 1;25(1):7–18. doi:10.1177/1535676019899502 PubMed PMID: 36033383; PubMed Central PMCID: PMC9134621.
13. Therapeutic recombinant protein production in plants: Challenges and opportunities - Burnett - 2020 - PLANTS, PEOPLE, PLANET - Wiley Online Library [Internet]. [cited 2026 May 1]. Available from: <https://nph.onlinelibrary.wiley.com/doi/full/10.1002/ppp3.10073>
14. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. *Sig Transduct Target Ther.* 2022 Feb 14;7(1):48. doi:10.1038/s41392-022-00904-4
15. Lagassé HAD, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, et al. Recent advances in (therapeutic protein) drug development. *F1000Res.* 2017 Feb 7;6:113. doi:10.12688/f1000research.9970.1 PubMed PMID: 28232867; PubMed Central PMCID: PMC5302153.
16. Muheem A, Shakeel F, Jahangir MA, Anwar M, Mallick N, Jain GK, et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. *Saudi Pharmaceutical Journal.* 2016 Jul 1;24(4):413–28. doi:10.1016/j.jsps.2014.06.004
17. Vipra M, Patil N, Sivaram A. Applications of Recombinant DNA Technology. In: Patil N, Sivaram A, editors. *A Complete Guide to Gene Cloning: From Basic to Advanced* [Internet]. Cham: Springer International Publishing; 2022 [cited 2026 May 1]. p. 143–57. doi:10.1007/978-3-030-96851-9_9